BiotechTube

KW-2246 (fentanyl citrate)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pain

Conditions

Pain, Cancer

Trial Timeline

Jul 1, 2006 → —

NCT ID
NCT00355628

About KW-2246 (fentanyl citrate)

KW-2246 (fentanyl citrate) is a phase 2 stage product being developed by Kyowa Kirin for Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00355628. Target conditions include Pain, Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Pain were approved

Approved (20) Terminated (4) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
✅pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
✅Topical High dose Capsaicin + Topical PlaceboAstellas PharmaApproved
✅Solifenacin succinate treatment + Oxycodone and acetaminophen combination treatmentAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00683995Phase 3Completed
NCT00355628Phase 2Completed

Competing Products

20 competing products in Pain

See all competitors
ProductCompanyStageHype Score
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
PRF110- oily solution (Ropivacaine)PainReformPhase 2
25
PRF110PainReformPhase 2
21
PRF-108 + Placebo + Ropivacaine + PRF-110PainReformPhase 1/2
22
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
TRV130TrevenaPhase 2
17
LY3556050 + PlaceboEli LillyPhase 2
35
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) TabletsNanoform FinlandPhase 1
23
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
29
LY3526318 + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
17
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40